TECOS – the new study of cardiovascular safety of DPP-4 inhibitors

• Alexander S. Ametov
• Liudmila L. Kamynina

Abstract

The paper is presented the detailed review of TECOS Study – the third long-term RCS, devoted to the assessment of the cardiovascular safety of sitagliptin (first and the most studied representative of the DPP4 inhibitors). The TECOS Study confirmed of the cardiovascular safety of sitagliptin and gave us the answer on the key, unexpectedly originating questions from the early cardiovascular RCSs SAVOR-TIMI and EXAMINE.

Keywords:type 2 diabetes mellitus, TECOS, incretins, sitagliptin, cardiovascular safety

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)